Figure 4.

Effect of etomoxir on [¹⁸F]FPIA uptake in subcutaneous HSJD-GBM-001 and U87 glioma xenografts. [¹⁸F]FPIA uptake was evaluated in control and etomoxir-treated mice using PET imaging and ex vivo biodistribution studies. Representative PET images, tumor time activity curves (NUVs) and biodistribution (%injected radioactivity/g normalized to blood, ex-vivo γ-counting) of [¹⁸F]FPIA in (a) U87 and (b) HSJD-GBM-001 tumors, and (c) [¹⁸F]FPIA tumor uptake (NUVs, 40–60 min and %injected activity/g normalized to blood) in control and etomoxir-treated mice. Treatment with etomoxir significantly decreased [¹⁸F]FPIA uptake (NUVs, 40–60 min and % injected radioactivity/g, * p = 0.01 and ** p < 0.005, respectively, Student’s t tests) in both HSJD-GBM-001 and U87 tumors. No significant changes in radiotracer uptake were observed in the blood or any of the other tissues examined in response to etomoxir.